Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28046327 | 0.84 | NR4A2 (0.49) | NR4A2CREBBPFFAR1GPR84HTR2A | |
| SCHEMBL9937305 | 0.83 | NR4A2 (0.70) | NR4A2CREBBPGPR84MAP2K1 | |
| SCHEMBL16234666 | 0.82 | PBRM1 (0.54) | NR4A2CREBBPFFAR1GPR84HTR2A | |
| SCHEMBL26250363 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1MAPT | |
| SCHEMBL5329797 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPHTR2AHTR2CHTR2B | |
| SCHEMBL3554889 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL9937058 | 0.81 | NR4A2 (1.00) | NR4A2CREBBPGPR84MAP2K1 | |
| SCHEMBL2034897 | 0.80 | GPR84 (0.51) | NR4A2FFAR1GPR84HTR2AALB | |
| SCHEMBL10083723 | 0.79 | HTR2A (0.47) | NR4A2FFAR1GPR84HTR2AALB | |
| SCHEMBL23160620 | 0.79 | GPR84 (0.50) | NR4A2FFAR1GPR84HTR2AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105593211-B | Indole and indazole derivatives | 豪夫迈·罗氏有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3049391-B1 | INDOLE AND INDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-9708259-B2 | Indol and indazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3049391-A1 | INDOL AND INDAZOL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207885-A1 | INDOL AND INDAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| CN-105593211-A | Indol and indazol derivatives | HOFFMANN LA ROCHE | 2016-05-18 | — | — | CN | disclosed |
| WO-2015044072-A1 | INDOL AND INDAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-02 | — | — | WO | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| CN-102770425-A | Indolyl-piperidinylbenzylamines as beta-tryptase inhibitors | SANOFI SA | 2012-11-07 | — | — | CN | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885FFAR1 3638/4885 |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | NR4A2 3953/4885CREBBP 2114/4885FFAR1 2143/4885 |
| US-20160207885-A1 | INDOL AND INDAZOL DERIVATIVES | CHRNA7, CHRM1, CHRNA3 | NR4A2 135/4885CREBBP 3182/4885FFAR1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.